Search clinical trials for: first time in human

Total 458897 results

ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
Eli Lilly and Company

Recruiting

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Elevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)

United States, Australia, Spain, Canada, Argentina, China, Italy, France, Japan, Taiwan, Korea, Republic of, Denmark, Germany, Hungary, Israel, Austria, Belgium, Netherlands, Brazil, Mexico, Romania, United Kingdom, Greece, Czechia, Poland and more
GlaxoSmithKline

Not yet recruiting

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

Systemic Lupus Erythematosus

United Kingdom
GlaxoSmithKline
Medicines for Malaria Venture

Recruiting

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Malaria, Falciparum

United Kingdom
Nanjing Medical University

Recruiting

Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.

Myocardial Fibrosis | Cardiac Rehabilitation

China
Onward Therapeutics

Recruiting

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Solid Tumor | Hematological Malignancy

France
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Hematologic Diseases | Anaemia, Sickle Cell

United States
ViiV Healthcare

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

HIV Infections

United States
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
GlaxoSmithKline

Recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Neoplasms

United States, Australia, Spain, Canada, France, Korea, Republic of, United Kingdom, Japan, China
University of Minnesota
National Institute of Mental Health (NIMH)

Recruiting

EPI-MINN: Targeting Cognition and Motivation

Psychosis

United States
ANRS, Emerging Infectious Diseases

Recruiting

Prevention of Mental Health Problems Among Persons Without Personal Housing in the Context of the COVID-19 Epidemic (RESPOND-FR)

Quality of Life | Psychological Distress | Psychosocial Intervention

France
GlaxoSmithKline
23andMe, Inc.; iTeos Therapeutics

Recruiting

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Neoplasms

United States, Canada, Korea, Republic of, Japan
Qilu Hospital of Shandong University
Shandong Provincial Hospital; Qingdao Municipal Hospital; China-Japan Friendship... and other collaborators

Recruiting

Bevacizumab in Patients With Severe Covid-19 (BEST)

COVID-19 Pneumonia

China
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
GlaxoSmithKline

Active, not recruiting

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Neoplasms

Spain, Netherlands, United States, Japan, France, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma | Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IV... and other conditions

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
GlaxoSmithKline

Terminated

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Neoplasms

Germany, United States, Netherlands, Canada, Australia, Sweden
CSL Behring

Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Acute Coronary Syndrome

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvi... and more
GlaxoSmithKline

Terminated

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

Heart Failure

United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
AstraZeneca

Active, not recruiting

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Melanoma | Cervical Cancer | Small Cell Lung Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Non-Small-Cell Lung Cancer | Gastroesophageal Cancer | Clear Cell Renal Cell Cancer | Squamous Cell Cancer of Head and Neck

United States, Spain, Canada, France
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Virus Diseases

United States
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)

Infections, Soft Tissue

United States, South Africa, Australia, India, New Zealand, United Kingdom, Poland
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

Leishmaniasis

United Kingdom
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

Pulmonary Disease, Chronic Obstructive

United Kingdom
SciNeuro

Completed

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Neurodegenerative Diseases | Alzheimer's Disease

Australia
GlaxoSmithKline

Withdrawn

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

Colitis, Ulcerative

United Kingdom
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Peripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin

Italy
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
ViiV Healthcare

Completed

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

HIV Infections

United States
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

Adenocarcinoma of the Rectum | Stage II Rectal Cancer | Stage III Rectal Cancer

United States, Canada, Puerto Rico, Peru
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole

Celiac Disease | Coeliac Disease

United Kingdom
Gan and Lee Pharmaceuticals, USA

Completed

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Diabetes Mellitus, Type 2

United States
GlaxoSmithKline

Terminated

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects

Leishmaniasis

United Kingdom
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Scancell Ltd

Active, not recruiting

A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection

COVID-19

South Africa
AstraZeneca

Completed

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Heart Failure

United States
GlaxoSmithKline

Terminated

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Neoplasms

United States, Spain, Canada, Australia
BerGenBio ASA

Completed

A First-time-in-human Study of BGB149

Healthy Volunteers

United Kingdom
Ivashkin Vladimir Trofimovich
Abbott

Completed

Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD

Gastroesophageal Reflux Disease (GERD)

Russian Federation
AstraZeneca
Parexel

Completed

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Metabolic Disorders | Non-alcoholic Steatohepatitis

United States
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States

Search clinical trials for: first time in human

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations